ClinicalTrials.Veeva

Menu

Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer

C

Chinese Alliance Against Lung Cancer

Status

Unknown

Conditions

Solitary Pulmonary Nodule
Multiple Pulmonary Nodules

Study type

Observational

Funder types

Other

Identifiers

NCT02726633
CAALC-004-Prolung

Details and patient eligibility

About

A Study to evaluate the utility of the ProLung China Test as an adjunct to CT scan in the diagnosis of lung cancer.

Full description

This Study will assess the stability of the ProLung China Test classification algorithm when used as an adjunct to CT scan. This Study will assess whether there are any potential safety concerns of the ProLung China Test when used to evaluate patients with a positive CT scan for lung cancer.

Enrollment

500 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Subject is male or female, age 18 to 80.
  2. Subject has undergone CT scan of the lung(s) that indicates one or more nodules or lesions.
  3. Subject's pulmonary nodule or lesion is greater than 4mm and smaller than 50mm. Size is determined by the largest nodule or lesion dimension identified from CT imaging.
  4. Subject must be able to receive a ProLung China Test within 30 days of abnormal CT within 14 days prior to the tissue biopsy or surgical resection.

Exclusion criteria

  1. Subject has an implanted electronic device in the chest. Subject receiving therapy for suspected chest infection such as fungal infection or tuberculosis.
  2. Subject with diagnosed malignancy other than lung cancer who has 2 or more suspicious pulmonary nodules.
  3. Subject has received an invasive medical or surgical procedure within the thoracic cavity within 30 days prior to the ProLung China Test or within the previous 14 days for a bronchoscopic procedure.
  4. Subject presents with an anomalous physical or anatomical condition that precludes ProLung China Test measurement.
  5. Subject will have undergone unusually strenuous exercise within 24 hours.
  6. Subject who has significant systemic diseases such as uncontrolled diabetes, advanced heart failure, or a recent myocardial infarction, or other medical condition such as severe morbid obesity that in the judgment of the Principal Investigator would make him/her unsuitable for the Study.

Trial contacts and locations

3

Loading...

Central trial contact

Chunxue Bai, MD; Dawei Yang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems